2023
DOI: 10.1007/s12185-023-03618-7
|View full text |Cite
|
Sign up to set email alerts
|

New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination

Abstract: Vaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…12,17 Aplastic anemia, which is immune-mediated 18 and arises after the administration of an mRNA COVID-19 vaccine has been reported. 19–22 The most commonly reported hematologic abnormalities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans’ syndrome, and VITT. 23 Although the incidence of these severe hematologic adverse events is extremely low, their evolution may lead to life-threatening scenarios if treatment is not promptly initiated.…”
Section: Introductionmentioning
confidence: 99%
“…12,17 Aplastic anemia, which is immune-mediated 18 and arises after the administration of an mRNA COVID-19 vaccine has been reported. 19–22 The most commonly reported hematologic abnormalities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans’ syndrome, and VITT. 23 Although the incidence of these severe hematologic adverse events is extremely low, their evolution may lead to life-threatening scenarios if treatment is not promptly initiated.…”
Section: Introductionmentioning
confidence: 99%